Bursal Hexapeptide, A Potential Immunomodulator, Inhibits Tumor Cells Proliferation via p53 Signaling Pathway

Author(s): Cong Zhang, Jiangfei Zhou, Shengnan Li, Kairui Cai, Xiangling Guo, Chengshui Liao*, Chen Wang*

Journal Name: Anti-Cancer Agents in Medicinal Chemistry
(Formerly Current Medicinal Chemistry - Anti-Cancer Agents)

Volume 18 , Issue 11 , 2018

Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Background: The Bursa of Fabricius (BF) is acknowledged as the central humoral immune organ unique to birds. Bursal Hexapeptide (BHP, AGCCNG) is a recently reported bursal-derived bioactive peptide. However, there are few reports of the molecular basis of the mechanism on immune induction and potential antitumor activity of BHP.

Method: In this paper, Gene microarray analyses demonstrated that BHP regulated expression of 1347 genes, of which 832 were up-regulated and 515 were down-regulated. Differentially expressed genes involved in various pathways were identified, of which 16 pathways were associated with immune responses and tumorigenic processes.

Result: Specifically, we found that BHP selectively inhibited tumor cell proliferation. Furthermore, BHP enhanced antitumor factor p53 luciferase activity and stimulated expression of p53, p21, and p130 protein. Moreover, we observed that the inhibitory effect of BHP on cell proliferation and premature senescence in a p53-dependent manner.

Conclusion: Taken together, we uncovered that BHP may be involved in antitumor suppressor via p53 signaling pathway.

Keywords: The bursa of Fabricius, bursal hexapeptide, gene microarrays, antiproliferation, p53 signaling pathway, immunomodulator.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2018
Published on: 28 January, 2019
Page: [1582 - 1588]
Pages: 7
DOI: 10.2174/1871520618666180604094618
Price: $65

Article Metrics

PDF: 22